,3 Activating mutations of the rapidly accelerated fibrosarcoma B-type (BRAF) gene are found in approximately 60% of cutaneous melanomas,4 and the therapeutic potential of BRAF inhibition has been harnessed. Here, BRAF is linked to fibrosarcoma.